Evidence map›Paper›PMID 33348363›Full record

ArticleBrain : a journal of neurology2021

Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder.

Dario Arnaldi, Andrea Chincarini, Michele T Hu, Karel Sonka, Bradley Boeve, Tomoyuki Miyamoto, Monica Puligheddu, Valérie Cochen De Cock, Michele Terzaghi, Giuseppe Plazzi and 23 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Brain : a journal of neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01453127 (DaTSCAN Imaging in Aging and Neurodegenerative Disease), which is not on this map. Cited by 68 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 2 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01453127 phase4enrolling by invitationnot on this map

DaTSCAN Imaging in Aging and Neurodegenerative Disease

TypeinterventionalSponsorMayo ClinicRan2011 to 2026Enrolled500ConditionsDementia, Parkinsonism, Mild Cognitive Impairment, REM Sleep Behavior DisorderArmsI-123 Ioflupane solution injection prior to SPECT scan (DaTscan), Single photon emission computed tomography (SPECT) scan
3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 125 citations in OpenAlex.

  1. Pooled it
  2. Post-Traumatic Stress Disorder and Risk of Degenerative Synucleinopathies: Systematic Review and Meta-Analysis.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2023
    Pooled it
  3. Article
  4. Review
  5. Observational
  6. Article
  7. Review
  8. Article
  9. Article
  10. Neuroimaging in multiple system atrophy: clinical implications and novel developments.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Unveiling Cortical Criticality Changes along the Prodromal to the Overt Continuum of Alpha-Synucleinopathy.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 16 institutions in 6 countries.

Dario ArnaldiClinical Neurology, Department of Neuroscience (DINOGMI), University of Genoa, Italy.
Andrea ChincariniNational Institute of Nuclear Physics (INFN), Genoa section, Genoa, Italy.
Michele T HuOxford Parkinson's Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Karel SonkaDepartment of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Bradley BoeveDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Tomoyuki MiyamotoDepartment of Neurology, Dokkyo Medical University Saitama Medical Centre, Saitama, Japan.
Monica PulighedduSleep Disorder Centre, Department of Medical Sciences and Public Health, University of Cagliari, Italy.
Valérie Cochen De CockDepartment of Sleep and Neurology, Beau Soleil Clinic, and EuroMov Digital Health in Motion, University of Montpellier, Montpellier, France.
Michele TerzaghiUnit of Sleep Medicine and Epilepsy, IRCCS Mondino Foundation, Pavia, Italy.
Giuseppe PlazziDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Naoko TachibanaDivision of Sleep Medicine, Kansai Electric Power Medical Research Institute, Osaka, Japan.
Silvia MorbelliIRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Michal RolinskiOxford Parkinson's Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Petr DusekDepartment of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Val LoweDepartment of Nuclear Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Masayuki MiyamotoCentre of Sleep Medicine, Dokkyo Medical University Hospital, Tochigi, Japan.
Michela FigorilliSleep Disorder Centre, Department of Medical Sciences and Public Health, University of Cagliari, Italy.
Delphine de VerbizierNuclear Medicine Unit, University hospital of Montpellier, France.
Irene BossertNuclear Medicine Unit, ICS Maugeri SpA SB IRCCS, Pavia, Italy.
Elena AntelmiDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Riccardo MeliClinical Neurology, Department of Neuroscience (DINOGMI), University of Genoa, Italy.
Thomas R BarberOxford Parkinson's Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Jiří TrnkaInstitute of Nuclear Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Toji MiyagawaDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Alessandra SerraNuclear Medicine Unit, Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
Fabio PizzaDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Matteo BaucknehtIRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Kevin M BradleyPETIC, University Hospital of Wales, Cardiff, UK.
David ZogalaInstitute of Nuclear Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Daniel R McGowanRadiation Physics and Protection Department, Churchill Hospital, Oxford, UK.
Lennon JordanDepartment of Nuclear Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Raffaele ManniUnit of Sleep Medicine and Epilepsy, IRCCS Mondino Foundation, Pavia, Italy.
Flavio NobiliClinical Neurology, Department of Neuroscience (DINOGMI), University of Genoa, Italy.
Ospedale Policlinico San Martino · ITCharles University · CZMayo Clinic · USJohn Radcliffe Hospital · GBUniversity of Cagliari · ITDokkyo Medical University · JPIstituto delle Scienze Neurologiche di Bologna · ITCentre Hospitalier Universitaire de Montpellier · FRChurchill Hospital · GBIstituti Clinici Scientifici Maugeri · ITIstituto Nazionale di Fisica Nucleare · ITKansai Electric Power (Japan) · JPUniversité de Montpellier · FRUniversity Hospital of Wales · GBUniversity of Pavia · ITUniversity of Verona · IT

Funding

Longitudinal Imaging Biomarkers of Prodromal DLBU01NS100620 · NINDS · MAYO CLINIC ROCHESTER · PI Bradley F Boeve, KEJAL KANTARCI · 2017 to 2026
$19.2M
Medical Research Council MC_EX_MR/N50192X/1Medical Research Council MR/L023784/1Medical Research Council MR/M024962/1NINDS NIH HHS U01 NS100620Parkinson's UK J-0901
6 · The paper itself

Abstract

This is an international multicentre study aimed at evaluating the combined value of dopaminergic neuroimaging and clinical features in predicting future phenoconversion of idiopathic REM sleep behaviour (iRBD) subjects to overt synucleinopathy. Nine centres sent 123I-FP-CIT-SPECT data of 344 iRBD patients and 256 controls for centralized analysis. 123I-FP-CIT-SPECT images were semiquantified using DaTQUANTTM, obtaining putamen and caudate specific to non-displaceable binding ratios (SBRs). The following clinical variables were also analysed: (i) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale, motor section score; (ii) Mini-Mental State Examination score; (iii) constipation; and (iv) hyposmia. Kaplan-Meier survival analysis was performed to estimate conversion risk. Hazard ratios for each variable were calculated with Cox regression. A generalized logistic regression model was applied to identify the best combination of risk factors. Bayesian classifier was used to identify the baseline features predicting phenoconversion to parkinsonism or dementia. After quality check of the data, 263 iRBD patients (67.6 ± 7.3 years, 229 males) and 243 control subjects (67.2 ± 10.1 years, 110 males) were analysed. Fifty-two (20%) patients developed a synucleinopathy after average follow-up of 2 years. The best combination of risk factors was putamen dopaminergic dysfunction of the most affected hemisphere on imaging, defined as the lower value between either putamina (P < 0.000001), constipation, (P < 0.000001) and age over 70 years (P = 0.0002). Combined features obtained from the generalized logistic regression achieved a hazard ratio of 5.71 (95% confidence interval 2.85-11.43). Bayesian classifier suggested that patients with higher Mini-Mental State Examination score and lower caudate SBR asymmetry were more likely to develop parkinsonism, while patients with the opposite pattern were more likely to develop dementia. This study shows that iRBD patients older than 70 with constipation and reduced nigro-putaminal dopaminergic function are at high risk of short-term phenoconversion to an overt synucleinopathy, providing an effective stratification approach for future neuroprotective trials. Moreover, we provide cut-off values for the significant predictors of phenoconversion to be used in single subjects.

Indexed as

AgedCaudate NucleusDopamine Plasma Membrane Transport ProteinsFemaleHumansKaplan-Meier EstimateMaleMiddle AgedPutamenREM Sleep Behavior DisorderRetrospective StudiesROC CurveSynucleinopathiesTomography, Emission-Computed, Single-PhotonTropanes2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropaneDopamine Plasma Membrane Transport ProteinsTropanesdementia with Lewy bodiesParkinson’s diseaseREM sleep behaviour disorderSPECT

Identifiers

PMID33348363
PMCPMC8599912
OpenAlexW3117271050

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.